|

Effect of Diosmin/Hesperidin Combination on Platinum Compounds-Induced Nephropathy in Cancer Patients

RECRUITINGPhase 4Sponsored by Beni-Suef University
Actively Recruiting
PhasePhase 4
SponsorBeni-Suef University
Started2025-02-03
Est. completion2026-11-03
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07598214

Summary

The current study aims to investigate the protective properties of diosmin/hesperidin on cisplatin-induced nephrotoxicity.

Eligibility

Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

* Patients of 18 to 75 year-age must have histologically or cytologically confirmed cancer by the Laboratory of Pathology receiving a platinum compound chemotherapy.

Exclusion Criteria:

* -History of allergic reactions attributed to drugs in the study.
* Pregnant women.
* Life expectancy less than 6 months
* Inability or unwillingness to comply with research protocols.
* Cancer patients with impaired renal function (creatinine clearance \< 50 mL/min)
* Preexisting hearing loss.
* Patients taking nephrotoxic drugs; and those who have a history of allergic reactions to platinum-containing compounds.

Conditions2

CancerCancer Patients

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.